CA1113935A - Geldanamycin derivatives and antitumor drug - Google Patents

Geldanamycin derivatives and antitumor drug

Info

Publication number
CA1113935A
CA1113935A CA345,489A CA345489A CA1113935A CA 1113935 A CA1113935 A CA 1113935A CA 345489 A CA345489 A CA 345489A CA 1113935 A CA1113935 A CA 1113935A
Authority
CA
Canada
Prior art keywords
geldanamycin
produced
chloroform
chemical equivalent
obvious chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA345,489A
Other languages
English (en)
French (fr)
Inventor
Kazuya Sasaki
Yukio Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1721879A external-priority patent/JPS55111469A/ja
Priority claimed from JP1721979A external-priority patent/JPS55111470A/ja
Priority claimed from JP1786879A external-priority patent/JPS55111485A/ja
Priority claimed from JP2138079A external-priority patent/JPS55113767A/ja
Application filed by Kaken Chemical Co Ltd filed Critical Kaken Chemical Co Ltd
Application granted granted Critical
Publication of CA1113935A publication Critical patent/CA1113935A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA345,489A 1979-02-19 1980-02-13 Geldanamycin derivatives and antitumor drug Expired CA1113935A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP1721879A JPS55111469A (en) 1979-02-19 1979-02-19 Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JP17218/1979 1979-02-19
JP17219/1979 1979-02-19
JP1721979A JPS55111470A (en) 1979-02-19 1979-02-19 Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JP1786879A JPS55111485A (en) 1979-02-20 1979-02-20 Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JP17868/1979 1979-02-20
JP21380/1979 1979-02-27
JP2138079A JPS55113767A (en) 1979-02-27 1979-02-27 Novel geldanamycin derivative, its preparation and antitumorigenic agent containing the same as effective component

Publications (1)

Publication Number Publication Date
CA1113935A true CA1113935A (en) 1981-12-08

Family

ID=27456741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA345,489A Expired CA1113935A (en) 1979-02-19 1980-02-13 Geldanamycin derivatives and antitumor drug

Country Status (8)

Country Link
US (1) US4261989A (OSRAM)
AU (1) AU532333B2 (OSRAM)
CA (1) CA1113935A (OSRAM)
DE (1) DE3006097A1 (OSRAM)
FR (1) FR2449084A1 (OSRAM)
GB (1) GB2042523B (OSRAM)
IT (1) IT1147315B (OSRAM)
NL (1) NL8000857A (OSRAM)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3234203A1 (de) * 1981-09-17 1983-07-07 Takeda Chemical Industries, Ltd., Osaka Macbecin-derivate und deren herstellung
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS59102398A (ja) * 1982-12-03 1984-06-13 Takeda Chem Ind Ltd 新規抗生物質およびその製造法
WO1994008578A2 (en) * 1992-10-14 1994-04-28 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
EP0828418A4 (en) * 1995-05-02 2000-03-29 Univ California INDUCTION OF THERMOTOLERANCE WITH BENZOCHINOIDS ANSAMYCINES
US6670348B1 (en) 1997-05-14 2003-12-30 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
PL349028A1 (en) * 1998-12-07 2002-07-01 Ecosmart Technologies Cancer treatment composition and method using natural plant essential oils
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
US7238682B1 (en) 1999-04-09 2007-07-03 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
US6979574B1 (en) * 1999-08-06 2005-12-27 Institut Fuer Diagnostik Forshung Gmbh Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
AU2001271567A1 (en) * 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
WO2002036171A1 (en) 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
WO2002069900A2 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
MXPA03007856A (es) * 2001-03-30 2003-12-04 Us Health Derivado de geldanamicina y metodo de usarlo para tratar cancer.
WO2002094196A2 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
CN100378079C (zh) * 2001-09-24 2008-04-02 康福玛医药公司 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
WO2003086381A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP4717003B2 (ja) 2003-11-12 2011-07-06 コーサン バイオサイエンシーズ， インコーポレイテッド １１−ｏ−メチルゲルダナマイシン化合物
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP4869077B2 (ja) * 2003-12-23 2012-02-01 インフィニティー ディスカヴァリー インコーポレイテッド 癌治療に使用するベンゾキノン包含アンサマイシン類のアナログ
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
WO2005105077A1 (en) * 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
WO2006089207A2 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
EP1869027A4 (en) * 2005-03-30 2010-06-23 Conforma Therapeutics Corp ALKYNYL-PYRROLOPYRIMIDINES AND CORRESPONDING ANALOGS AS HSP90 INHIBITORS
US20060228405A1 (en) * 2005-04-07 2006-10-12 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
KR20080009196A (ko) 2005-04-12 2008-01-25 위스콘신 얼럼나이 리서어치 화운데이션 중합체 및 패신저 약물의 마이셀 조성물
MX2007013494A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070129342A1 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions Containing Ansamycin
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
BRPI0713637A2 (pt) 2006-06-12 2012-10-23 Sunesis Pharmaceuticals Inc composição, composto, e , método para o tratamento de cáncer
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101688227B (zh) * 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
EP2134338A1 (en) * 2007-04-12 2009-12-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
NZ580313A (en) * 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
EP2180880A2 (en) * 2007-07-09 2010-05-05 Glen S. Kwon Micelle encapsulation of therapeutic agents
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
AU2009243056B2 (en) * 2008-04-29 2015-05-14 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8778921B2 (en) * 2008-10-15 2014-07-15 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
KR101721281B1 (ko) 2009-09-25 2017-04-10 위스콘신 얼럼나이 리서어치 화운데이션 치료제의 미셀 캡슐화
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
MX351961B (es) 2011-04-22 2017-10-17 Joyant Pharmaceuticals Inc Analogos de diazonamida.
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
CN106474127A (zh) 2011-10-14 2017-03-08 诺华股份有限公司 用于治疗增生性疾病的2‑甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合
WO2013074695A1 (en) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
HK1205758A1 (en) 2012-01-09 2015-12-24 Novartis Ag Rnai agents to treat beta-catenin related diseases
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
JP2015536986A (ja) 2012-11-07 2015-12-24 ノバルティス アーゲー 併用療法
HRP20180816T1 (hr) 2013-02-19 2018-06-29 Novartis Ag Derivati benzotiofena i njihovi sastavi kao sredstva za selektivnu degradaciju receptora estrogena
CN103360312B (zh) * 2013-07-22 2015-06-03 山东大学 一组格尔德霉素衍生物及其应用
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
RU2017134379A (ru) 2015-03-25 2019-04-03 Новартис Аг Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
CN108024989B (zh) 2015-06-12 2021-08-03 威斯康星校友研究基金会 用作强效放射敏化剂的多药组合
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3023032A1 (en) 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
CN118684652A (zh) 2017-09-11 2024-09-24 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102643582B1 (ko) 2018-07-25 2024-03-05 어드밴스드 엑셀러레이터 어플리케이션즈 안정한 농축 방사성 핵종 복합체 용액
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN112867512A (zh) 2018-09-25 2021-05-28 意大利国际先进加速器应用有限公司 联合疗法
JP2022502496A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
SG11202102981SA (en) 2018-09-25 2021-04-29 Black Diamond Therapeutics Inc Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
KR102820455B1 (ko) 2018-09-29 2025-06-16 노파르티스 아게 Shp2 활성 억제용 화합물의 제조 방법
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
AU2021409561A1 (en) 2020-12-22 2023-07-06 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4323350A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone compounds
EP4323349A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors
JP2025509886A (ja) 2022-03-28 2025-04-11 ニカング セラピューティクス， インコーポレイテッド サイクリン依存性キナーゼ２阻害剤としてのスルホンアミド誘導体
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
TW202434563A (zh) 2022-11-11 2024-09-01 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２的含有２，５－取代的嘧啶衍生物之雙功能化合物
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025117616A1 (en) 2023-11-27 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025212828A1 (en) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds

Also Published As

Publication number Publication date
IT8020017A0 (it) 1980-02-19
AU5443080A (en) 1980-08-28
GB2042523A (en) 1980-09-24
AU532333B2 (en) 1983-09-29
FR2449084A1 (fr) 1980-09-12
IT1147315B (it) 1986-11-19
FR2449084B1 (OSRAM) 1983-12-23
GB2042523B (en) 1983-02-09
NL8000857A (nl) 1980-08-21
DE3006097C2 (OSRAM) 1991-11-07
DE3006097A1 (de) 1980-08-28
US4261989A (en) 1981-04-14

Similar Documents

Publication Publication Date Title
CA1113935A (en) Geldanamycin derivatives and antitumor drug
DE69033335T2 (de) DC-88A-Derivate
KR100292592B1 (ko) 세로토닌길항제로서의n-시아노n'-피리딜구아니딘
EP0266349B1 (de) Tricyclische indolderivate, herstellung und anwendung als arzneimittel
JPH052671B2 (OSRAM)
US5219840A (en) Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US20030171376A1 (en) Methotrexate derivatives
DE69128477T2 (de) Benzopyranderivat
SE446974B (sv) Nya terpenoider, forfarande for framstellning av dessa samt farmaceutiska kompositioner, verksamma mot magsar, innehallande dessa
EP0255894B1 (de) Pyrimidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten
JPS6354395A (ja) 免疫抑制物質類、それらの製造法およびそれらを含有する製薬学的組成物
EP0052333A1 (en) 4-Fluoro-5-oxypyrazole derivate and preparation thereof
CA1215990A (en) Method of modulating the immune response in mammals
HU191682B (en) Process for preparing 1-benzyl-azetidin-3-ol derivatives
EP0233841A1 (de) Chinon-Derivate und Verfahren zu ihrer Herstellung
US5374711A (en) Chemical modification of 2"-amino group in elsamicin a
WO1996016053A1 (en) Phthalide compounds and their production process
DE2740678A1 (de) 1-amino-2-hydroxy-3-heterocycloxypropane
EP0099091B1 (en) Hexahydrodioxopyrimidines, their production and use
US4485248A (en) Process for producing 2,4-diamino-(3,5-dimethoxy-4-methoxyethoxy-benzyl)-pyrimidine
JPH0331193B2 (OSRAM)
US4521606A (en) 5-Indolyl substituted aminoethanols
RU2102390C1 (ru) N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
DE2408666A1 (de) Antibiotische derivate und verfahren zu deren herstellung
EP0332080B1 (en) Bu-3862t antitumor antibiotic

Legal Events

Date Code Title Description
MKEX Expiry